Aptorum Group Unveils New Plasma MicroRNA Biomarker Data at Alzheimer’s Conference

Reuters11-19
Aptorum Group Unveils New Plasma MicroRNA Biomarker Data at Alzheimer's Conference

Aptorum Group Ltd., in collaboration with DiamiR Biosciences, has announced the acceptance of two poster presentations for the upcoming 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, scheduled for December 1-4, 2025, in San Diego, California, and online. The presentations will focus on the development and characterization of brain-enriched and inflammation-associated microRNAs as potential plasma biomarkers for neurodegeneration. The studies involve collaborations with the New York University (NYU) Alzheimer's Disease Research Center and the University of Pennsylvania Alzheimer's Disease Research Center. The research was supported by funding from the National Institute on Aging (NIA) of the National Institutes of Health. The results will be presented at the conference and have not yet been disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptorum Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9578655-en) on November 19, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment